CBD stakeholders hoping for clarity in US regulations were left disappointed by the passing of the $1.5tn omnibus spending bill earlier this month as some helpful language was dropped during the final negotiations.

Originally the US Senate Appropriations Committee incorporated sought-after language in its Agriculture, Rural Development, Food and Drug Administration (FDA), and Related Agencies Appropriations Bill that would eventually form part of the so-called omnibus bill.

The language in the Senate’s version included a directive instructing the US Food and Drug Administration (FDA) to publish a policy outlining enforcement discretion, within 90 days of the bill becoming law. This would have brought clarity to the market and been welcomed by all sectors.

I'm already a subscriber
Author default picture


Staff member
CannIntelligence contributor.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization